Interview with Julianna Lisziewicz, President, Genetic Immunity
Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a…
Address: Berlini str. 47-49, H-1045Budapest,Hungary
Tel: +36 1 272 0364
Web: http://www.geneticimmunity.com/GI00.html
Genetic Immunity is a privately held US/Hungarian clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of immunotherapeutic biologics (‘Immune Therapies’ or ‘Therapeutic Vaccines’) for the treatment of chronic viral infections, cancer and allergy. Our Immune Therapies are designed to intensify or boost specific immune responses to modify or control these presently incurable diseases. We believe that our Products will allow people to live a better and longer life.
Our proprietary Immune Therapy Platform Technology includes the plasmid DNA-based antigen design, nanomedicine formulation and topical administration targeting antigens to dendritic cells. Our technologies support the rapid and cost-effective development of original biologic Products for several indications and provide tools for the selection of an optimal treatment for every patient based on his disease and genetic background.
Our lead Product candidate for the treatment of HIV/AIDS, referred to as ‘DermaVir’, is a therapeutic HIV vaccine effective in boosting immune responses that kill HIV-infected cells. Our Phase I and Phase II clinical trials demonstrated boosting of HIV-specific T cells and specific killing of HIV-infected cells that are not eliminated by current antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir immune intensification is to modify HIV disease, decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels and achieve a remission (functional cure) in HIV-infected patients.
Our pipeline product candidate with animal proof of concept, for the treatment of Chlamydia infection, is referred to as ‘ChlamyDerm’ and our allergen-specific immunotherapy is referred to as ‘DermAll’. ChlamyDerm decreased the amount of infected cells together with infection-associated inflammation in mice experiments. DermAll decreased the allergic symptoms by balancing allergen-specific immune responses in mice experiments. Other pipeline candidates for virus-associated cancers and warts are in discovery phase.
There are four principal components that comprise our comprehensive Immune Therapy platform technology which are designed to work in conjunction to treat and/or control chronic infectious diseases, cancer and allergy, as follows:
1.Our Active Pharmaceutical Ingredients (API):
We have been designing (ANTIGENeering) our APIs to be specific, safe and effective. It consists of a single plasmid DNA (pDNA) immunogen ANTIGENeered to express several antigens, to contain molecular safety features and to release Virus Like Particles (VLP+) in the body of the patients. API with these crucial properties is not feasible with protein or peptide antigens.
2.Nanomedicine – our Product platform:
Our Products are referred here as the ‘nanomedicine’ according to their unique biophysical and biological features. Our APIs are formulated with our novel polymer excipient to synthetic ‘pathogen-like’ nanoparticles. The nanomedicine formulation is essential to achieve potent antigen expression from the pDNA and antigen presentation by dendritic cells. This is critical for the intensification of antigen-specific immune responses in people with chronic diseases.
3.DermaPrep – our topical administration platform:
We have developed DermaPrep medical device for targeted in vivo delivery of our nanomedicine Products to the dendritic cells of the lymph nodes via the Langerhans cells. We obtained the Marketing Approval in the European Union (CE Mark) for our DermaPrep device.
4.IT – Applied information technology:
IT innovations have been supporting the discovery, development, manufacturing, and personalized treatment processes of Genetic Immunity. These include the rational antigen design, clinical trial and data management and matching the patients with the optimal Immune Therapy Product.
Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a…
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here